A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site — CUPISCO

Cancer of Unknown Primary Site Clinical Trial

Official title:
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Status Active, not recruiting

Clinical Trial Summary

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03498521
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 10, 2018
Completion date	June 9, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03278600` - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary	Phase 3
Recruiting	`NCT04504604` - TCF-001 TRACK (Target Rare Cancer Knowledge) Study	N/A
Completed	`NCT03053466` - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors	Phase 1
Active, not recruiting	`NCT04750109` - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting	`NCT04952103` - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting	`NCT04969835` - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours	Phase 1
Completed	`NCT01845337` - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine	Phase 2
Recruiting	`NCT05263700` - FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary	N/A
Active, not recruiting	`NCT03752333` - Trial of Pembrolizumab in Cancer of Unknown Primary	Phase 2
Completed	`NCT05841966` - Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary	N/A
Recruiting	`NCT04131621` - Nivolumab/Ipilimumab in Second Line CUP-syndrome	Phase 2
Recruiting	`NCT04459273` - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers	Phase 1
Active, not recruiting	`NCT05024968` - Sintilimab in Cancer of Unknown Primary	Phase 2